Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05346484 · ClinicalTrials.gov registry record · Phase 1
A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors
A Phase 1 study, sponsored by Imugene Limited.
- Terminated
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT05346484 is a Phase 1 study that was terminated before completion, run by Imugene Limited. The registered enrollment target is 66 participants.
The verdict
NCT05346484, a Phase 1 study, was terminated before completion, sponsored by Imugene Limited.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
This is an open-label, dose-escalation, multi-center phase I study evaluating the safety of CF33-hNIS (hNIS - human sodium iodide symporter) administered via two routes of administration, intratumoral (IT) or intravenous (IV), either as a monotherapy or in combination with pembrolizumab or mFOLFOX in patients with metastatic or advanced solid tumors.
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL CF33-hNIS
- DRUG Modified FOLFOX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2022-05-17 |
| Est. Completion | 2026-01-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05346484
The ClinicalTrials.gov registry entry for NCT05346484 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Imugene Limited, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT05346484 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05346484 about?
NCT05346484 is a clinical study titled "A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors". This is an open-label, dose-escalation, multi-center phase I study evaluating the safety of CF33-hNIS (hNIS - human sodium iodide symporter) administered via two routes of administration, intratumoral (IT) or intravenous (IV), either as a monotherapy or in combination with pembrolizumab or mFOLFOX i...
What is the current status of trial NCT05346484?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2022-05-17. Estimated completion is 2026-01-12.
What interventions are being tested in trial NCT05346484?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), CF33-hNIS (BIOLOGICAL), Modified FOLFOX (DRUG).
Who is sponsoring clinical trial NCT05346484?
This trial is sponsored by Imugene Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.